Target intelligence / Profile preview

60S ribosomal protein L12 (RPL12)

Target
RPL12
Molecular classification
Ribosomal protein (component of the large 60S subunit of the ribosome)[2][3], Structural constituent of ribosome[2][3]
01

Overview

60S ribosomal protein L12 (RPL12) is a structural protein that forms part of the large (60S) subunit of the eukaryotic ribosome, which functions as the cellular machinery for protein synthesis[2][3]. It binds directly to 26S rRNA and is located in the cytoplasm. RPL12 is imported into the nucleus by a distinct transport pathway mediated by importin 11, rather than the general importin system utilized by most ribosomal proteins[1]. This specialized pathway may serve to regulate ribosome assembly and maturation[1]. RPL12 belongs to the L11P family of ribosomal proteins and is evolutionarily conserved. Mutations or defects in RPL12 may be linked to disorders of ribosomal function, such as Diamond-Blackfan anemia[3]. There are currently no drugs that directly target this protein, and its ubiquitous essential role means that direct targeting would likely be toxic to normal cells.

Other names
Large ribosomal subunit protein uL11RPL12L12uL1160S ribosomal protein L12
02

Mechanism of action

Not applicable; no direct human drugs target RPL12. In bacteria, some antibiotics indirectly interfere with proteins analogous to L12, but this is outside human therapeutics.

03

Biological functions

Protein synthesis (translation)[2][3]RNA binding[3]Ribosome biogenesis (involving nuclear import via importin 11 pathway)[1]Structural support for large ribosomal subunit assembly[1][2][3]
04

Disease associations

Diamond-Blackfan anemia (defects in ribosomal proteins are associated with this rare inherited anemia)[3]Other: ribosomal protein dysfunction can contribute to ribosomopathies and may be implicated indirectly in certain cancers, but RPL12 is not a principal cancer biomarker[3]
05

Safety considerations

Challenges for targeting ribosomal proteins therapeutically include toxicity: the ribosome is ubiquitous and essential in all cells, so inhibition would severely impact general cellular protein synthesis and viability.

Beyond the preview

Go deeper on 60S ribosomal protein L12 (RPL12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 60S ribosomal protein L12 (RPL12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call